QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that the Corporation has filed a Patent Cooperation Treaty (PCT) patent application for seeking protection for thylakoids developed by the company such as Thykamine™ in wound healing.

魁北克市-（商业线）-临床阶段植物制药公司Devonian Health Group Inc.（“Devonian”或“Corporation”）（TSXv:GSD；OTCJB:DVHGF），专注于开发独特的植物药物和药妆产品组合，很高兴地宣布该公司已提交专利合作条约（PCT）专利申请，以寻求由该公司开发的类囊体保护，如Thykamine™ 在伤口愈合。

The filing of this PCT application will give the Corporation the option of seeking patent protection in about 157 PCT contracting states..

提交此PCT申请将为公司提供在约157个PCT合同州寻求专利保护的选择。。

“The filing of this new patent application is a key component of our broad strategy in expanding our robust patent estate. The patent application highlights the positive impact of thylakoids developed by the Corporation such as Thykamine™ on the wound healing cascade, for example, by increasing the production of collagen, Granulocyte Colony-Stimulating Factor and Granulocyte Macrophage Colony-Stimulating Factor.

“提交这项新的专利申请是我们扩大强大专利权的广泛战略的关键组成部分。专利申请突出了公司开发的类囊体如Thykamine的积极影响™ 在伤口愈合级联上，例如，通过增加胶原蛋白，粒细胞集落刺激因子和粒细胞-巨噬细胞集落刺激因子的产生。

Importantly, this filing is timely as we look to demonstrate the potential broad application of Thykamine™ as a therapeutic drug,” said Dr. André P. Boulet, Chief Scientific Officer of Devonian..

重要的是，当我们试图证明Thykamine潜在的广泛应用时，这个文件是及时的™ 作为一种治疗药物，”泥盆纪首席科学官AndréP.Boulet博士说。。

About Thykamine™

关于Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders.

Thykamine™, 第一个药品由泥盆纪SUPREX发行™ 平台是一种高度创新的产品，用于预防和治疗与炎症和氧化应激相关的健康状况，包括溃疡性结肠炎，特应性皮炎，牛皮癣，类风湿性关节炎和其他自身免疫性疾病。

The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a Phase II clinical study in patients with mild-to-moderate atopic dermatitis..

Thykamine的抗炎，抗氧化和免疫调节特性™ 已经通过相当多的体外和体内研究以及轻度至中度远端溃疡性结肠炎患者的IIa期临床研究和轻度至中度特应性皮炎患者的II期临床研究证明了这一点。。

About Devonian

关于泥盆纪

Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis.

Devonian Health Group Inc.是一家后期植物制药公司，具有针对未满足医疗需求的新型治疗方法。泥盆纪的核心战略是从植物材料和藻类开发处方植物药，用于治疗炎症性自身免疫性疾病，包括但不限于溃疡性结肠炎和特应性皮炎。

Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines..

基于15年以上研究的基础，泥盆纪的重点得到了美国FDA制定的一套监管指南的进一步支持，这些指南有利于处方植物药产品比传统处方药更有效的药物开发途径。。

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’.

泥盆纪还参与开发高价值药妆产品，利用与其药品相同的专有方法。Devonian Health Group Inc.于2015年成立，总部设在加拿大魁北克省，拥有最先进的提取设施，可完全追溯“从种子到药丸”。

Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF)..

其商业化子公司Altius Healthcare Inc于2018年收购，为进一步多样化和增长潜力带来了机会。泥盆纪在TSX风险交易所（“交易所”）（TSXV:GSD）和OTCQB交易所（OTCQB:DVHGF）公开交易。。

For more information, visit www.groupedevonian.com.

欲了解更多信息，请访问www.groupedevonian.com。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the PCT application, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release..

本新闻稿所载的所有陈述，除历史事实陈述外，包括但不限于与PCT申请有关的陈述，均构成某些证券法含义范围内的“前瞻性信息”或“前瞻性陈述”，并且基于本新闻稿发布时的期望，估计和预测。。

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.

前瞻性陈述必然基于一系列估计和假设，尽管公司在陈述时认为合理，但本质上会受到重大的业务，经济和竞争不确定性和意外事件的影响。这些估计和假设可能被证明是不正确的。

Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements..

许多这些不确定性和意外事件可能直接或间接影响并可能导致实际结果与任何前瞻性陈述中表达或暗示的结果大不相同。无法保证这些假设将被证明是正确的，并且无法保证前瞻性陈述将被证明是准确的，因为实际结果和未来事件可能与此类陈述中预期的事件有很大差异。。

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future.

就其本质而言，前瞻性陈述涉及一般性和具体性的固有风险和不确定性，存在估计，预测，预测和其他前瞻性陈述将无法实现或假设不能反映未来经验的风险。提供前瞻性声明是为了提供有关管理层对未来的期望和计划的信息。

Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements.

警告读者不要过分依赖这些前瞻性陈述，因为一些重要的风险因素和未来事件可能导致实际结果与信念，计划，目标，期望，预期，估计，假设和意图大不相同在这样的前瞻性陈述中表达。

All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law..

本新闻稿中所作的所有前瞻性声明均符合这些警示性声明以及我们与加拿大适用证券监管机构的其他文件中所作的声明。除适用法律规定的范围外，公司不承担更新或修改任何前瞻性陈述或解释后续实际事件与此类前瞻性陈述之间的任何重大差异的任何意图或义务。。

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

交易所或其监管服务提供商（如交易所政策中定义的那样）均不对本版本的充分性或准确性承担责任。